U.S. recommends a pause in Valneva chikungunya vaccine for those over 60

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review over serious adverse events linked to the single-dose